WallStSmart
CRBU

Caribou Biosciences Inc

NASDAQ: CRBU · HEALTHCARE · BIOTECHNOLOGY

$2.03
-7.02% today

Updated 2026-06-05

Market cap
$198.86M
P/E ratio
P/S ratio
17.75x
EPS (TTM)
$-1.42
Dividend yield
52W range
$1 – $4
Volume
1.6M

Caribou Biosciences Inc (CRBU) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-32.01M$-33.22M$-32.52M$-90.97M$-93.29M$-138.20M$-110.99M
Capital expenditures$884000.00$1.31M$3.12M$6.45M$11.61M$6.50M$1.36M
Depreciation
Stock-based comp$1.23M$1.00M$3.45M$11.72M$13.75M$16.71M$12.68M
Free cash flow$-32.89M$-34.53M$-35.64M$-97.42M$-104.90M$-144.71M$-112.35M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$224.51M$-182.08M

Frequently asked questions

What is Caribou Biosciences Inc's revenue?

Caribou Biosciences Inc's trailing twelve-month revenue is $11.20M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is CRBU?

In its most recent fiscal year, CRBU ran a gross margin of 67.34%, an operating margin of -1,220.49%, and a net margin of -1,327.40%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does CRBU generate?

CRBU produced $-112.35M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CRBU's balance sheet healthy?

CRBU holds $12.36M in cash and equivalents against — in long-term debt, on $122.17M of shareholder equity. That debt is best read against the cash flow the business throws off each year.